Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Operations

v3.25.1
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Operating expenses:    
Research and development $ 5,464,250 $ 2,123,778
General and administrative 1,995,845 1,552,873
Total operating expenses 7,460,095 3,676,651
Loss from operations (7,460,095) (3,676,651)
Other income (expense):    
Change in fair value of financial instruments   (14,132)
Interest expense   (76,775)
Other income 112,192 132,470
Total other income (expense), net 112,192 41,563
Net Loss $ (7,347,903) $ (3,635,088)
Net loss per share, basic $ (0.21) $ (0.19)
Net loss per share, diluted $ (0.21) $ (0.19)
Weighted-average shares outstanding of common shares, basic 34,851,203 19,533,976
Weighted-average shares outstanding of common shares, diluted 34,851,203 19,533,976